We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Moderna (MRNA) Stock Dips While Market Gains: Key Facts
Read MoreHide Full Article
Moderna (MRNA - Free Report) ended the recent trading session at $27.08, demonstrating a -3.77% change from the preceding day's closing price. The stock's change was less than the S&P 500's daily gain of 0.26%. Elsewhere, the Dow saw an upswing of 0.09%, while the tech-heavy Nasdaq appreciated by 0.61%.
The biotechnology company's shares have seen a decrease of 0.81% over the last month, not keeping up with the Medical sector's gain of 6.63% and the S&P 500's gain of 2.08%.
Market participants will be closely following the financial results of Moderna in its upcoming release. The company plans to announce its earnings on November 6, 2025. The company is expected to report EPS of -$2.15, down 7266.67% from the prior-year quarter. Simultaneously, our latest consensus estimate expects the revenue to be $860.07 million, showing a 53.81% drop compared to the year-ago quarter.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of -$9.74 per share and a revenue of $1.9 billion, representing changes of -9.81% and -41.4%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for Moderna. These recent revisions tend to reflect the evolving nature of short-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Within the past 30 days, our consensus EPS projection has moved 2.52% lower. As of now, Moderna holds a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 94, positioning it in the top 39% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Moderna (MRNA) Stock Dips While Market Gains: Key Facts
Moderna (MRNA - Free Report) ended the recent trading session at $27.08, demonstrating a -3.77% change from the preceding day's closing price. The stock's change was less than the S&P 500's daily gain of 0.26%. Elsewhere, the Dow saw an upswing of 0.09%, while the tech-heavy Nasdaq appreciated by 0.61%.
The biotechnology company's shares have seen a decrease of 0.81% over the last month, not keeping up with the Medical sector's gain of 6.63% and the S&P 500's gain of 2.08%.
Market participants will be closely following the financial results of Moderna in its upcoming release. The company plans to announce its earnings on November 6, 2025. The company is expected to report EPS of -$2.15, down 7266.67% from the prior-year quarter. Simultaneously, our latest consensus estimate expects the revenue to be $860.07 million, showing a 53.81% drop compared to the year-ago quarter.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of -$9.74 per share and a revenue of $1.9 billion, representing changes of -9.81% and -41.4%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for Moderna. These recent revisions tend to reflect the evolving nature of short-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Within the past 30 days, our consensus EPS projection has moved 2.52% lower. As of now, Moderna holds a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 94, positioning it in the top 39% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.